Comparative Pharmacology
Head-to-head clinical analysis: ARICEPT ODT versus RAZADYNE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARICEPT ODT versus RAZADYNE.
ARICEPT ODT vs RAZADYNE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible acetylcholinesterase inhibitor, increasing acetylcholine concentration in the synaptic cleft of central cholinergic neurons.
Galantamine is a reversible competitive acetylcholinesterase inhibitor and an allosteric modulator of nicotinic acetylcholine receptors, enhancing cholinergic function in the central nervous system.
5 mg orally once daily; may increase to 10 mg once daily after 4-6 weeks.
Initial dose 8 mg/day PO (4 mg twice daily) for 4 weeks; increase to 16 mg/day (8 mg twice daily) for at least 4 weeks; maintenance 16-24 mg/day (12 mg twice daily). Extended-release: initial 8 mg PO once daily; after 4 weeks increase to 16 mg once daily; if tolerated, may increase to 24 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 70 hours (range 50-80 hours). Clinical context: Steady-state achieved in 15-21 days; once-daily dosing maintains therapeutic concentrations.
Terminal elimination half-life is approximately 7-8 hours in healthy adults, allowing twice-daily dosing; unchanged in mild to moderate hepatic impairment but prolonged in severe hepatic impairment.
Renal: 57% (as unchanged drug and metabolites); Fecal: 15%; Biliary: minor
Renal excretion of unchanged drug accounts for approximately 20-25% of the dose; the remainder is metabolized by the liver and excreted as metabolites in urine (about 95% total) and feces (about 5%).
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor